Description
Research Overview
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been investigated for its ability to stimulate growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. Human research has demonstrated sustained increases in GH and IGF-1 following administration of CJC-1295.
Ipamorelin Research
Ipamorelin is a growth hormone-releasing peptide (GHRP) that has been studied for its effects on GH secretion. Experimental research has investigated its pharmacokinetic and pharmacodynamic characteristics and its selective activity at the GH secretagogue receptor.
Research Focus
The CJC-1295 + Ipamorelin combination is of interest in experimental research involving the GH/IGF-1 signalling axis, endocrine physiology, peptide pharmacology and mechanisms regulating growth hormone secretion.
Scientific Context
CJC-1295 and Ipamorelin act through different mechanisms involved in GH regulation, making the combination relevant to research examining interactions between GHRH signalling and growth hormone secretagogue pathways. Available research should be interpreted within the context of the specific experimental model and study conditions.
Important Research Note
Research involving these compounds does not establish that the combination is safe or effective for human performance, body composition, recovery or treatment of disease. Clinical evidence for this specific combination remains limited, and these compounds should not be treated as established therapeutic products.
For research purposes only. Not intended for human or veterinary use.
